Patents by Inventor Robert Ballotti
Robert Ballotti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240122938Abstract: The present invention relates to a compound ABT-263 or a derivative thereof for use in the treatment of uveal melanoma and/or uveal melanoma resistant. Inventors provide evidence that ABT-263 displays clear antiproliferative and proapoptotic activities in metastatic uveal melanoma cells both in vitro and in vivo. They also demonstrated that ABT-263 effect is accompanied with the activation of the ER stress response pathway that exerts cytoprotective effect. Blocking ER stress enhanced ABT-263 killing efficacy. The combination of ABT-263 with PERK inhibition synergistically reduced the survival rate of primary uveal melanoma cells.Type: ApplicationFiled: October 28, 2020Publication date: April 18, 2024Inventors: Robert BALLOTTI, Corine BERTOLOTTO-BALLOTTI
-
Publication number: 20230416838Abstract: Here, in multi-scale analyses using single-cell RNA sequencing of six different primary uveal melanomas, inventors uncover a previously unrecognized intratumor heterogeneity at the genetic and transcriptomic level. They identify distinct transcriptional cell states and diverse tumor-associated populations in a subset of primary uveal melanomas.Type: ApplicationFiled: November 15, 2021Publication date: December 28, 2023Inventors: Robert BALLOTTI, Thomas STRUB, Charlotte PANDIANI, Corine BERTOLOTTO-BALLOTTI
-
Publication number: 20230416830Abstract: Here, in multi-scale analyses using single-cell RNA sequencing of six different primary uveal melanomas, inventors uncover a previously unrecognized intratumor heterogeneity at the genetic and transcriptomic level. They identify distinct transcriptional cell states and diversetumor-associated populations in a subset of primary uveal melanomas. They also decipher a gene regulatory network underlying an invasive and poor prognosis state driven in part by the transcription factor HES6, a member of the NOTCH signaling pathway. HES6 heterogenous expression has been validated by RNAscope assays within primary uveal melanomas, which unveils the existence of these cells conveying a dismal prognosis in tumors diagnosed with a favorable outcome using bulk analyses. Depletion of HES6 impairs growth, migration and metastatic dissemination, demonstrating essential roles of HES6 in uveal melanoma progression.Type: ApplicationFiled: November 15, 2021Publication date: December 28, 2023Inventors: Robert BALLOTTI, Thomas STRUB, Charlotte PANDIANI, Corine BERTOLOTTO-BALLOTTI
-
Publication number: 20210072244Abstract: The present invention relates to a method for treating a subject suffering from melanoma resistant by administering to said subject an inhibitor of NAMPT. Using a global metabolic profiling, inventors have showed that in addition to glycolysis, the BRAF inhibitor, PLX4032, promoted a complex metabolic rewiring of melanoma cells, including protein catabolism and fatty acid synthesis. Importantly, they observed that PLX4032 reduced the levels of nicotinamide adenine dinucleotide (NAD+), an important redox co-factor in numerous metabolic processes, including glycolysis, tricarboxylic acid cycle (TCA) cycle, glutamate metabolism and fatty acid betaoxidation. Pharmacological or genetic inhibition of NAMPT impaired melanoma cell growth, whereas the overexpression of NAMPT dampened the antiproliferative effect of PLX4032. In vivo, the inhibition of NAMPT also prevented the xenograft development of PLX4032-sensitive and -resistant melanoma cells, identifying NAMPT as a potential target for BRAFi-resistant melanomas.Type: ApplicationFiled: January 3, 2019Publication date: March 11, 2021Inventors: Corine BERTOLOTTO, Mickaël OHANNA, Robert BALLOTTI
-
Publication number: 20210040054Abstract: The present invention relates to compound of general formula (I) R1 is selected from H, aryl and alkyl, R2 is selected from H, alkyl, aryl and CO—R6; R3 is selected from H, halogen, alkyl, alkenyl, alkynyl, aryl, NHR7, NR7R8, OR7 and SR7; R4 is selected from (C6-C12) alkyl, (C2-C12) alkenyl, (C2-C12) alkynyl and (C6-C10) aryl, R5 represents H, R6, aryl, OH, OR6, O-aryl, SH, SR6, S-aryl, CN, NO2, CF3, COOR6, SO2NR6R7, CONR6R7, NH2, NHR6, NH-aryl, NR6R7, NHCOR6 or aminoacyl; R6 is alkyl optionally substituted with halogen, OH, SH, NH2, O-alkyl, S-alkyl, NH-alkyl or NH-di(alkyl); R7 and R8 identical or different are H or alkyl optionally substituted with halogen, OH, SH, NH2, O-alkyl, S-alkyl, NH-alkyl or NH-di (alkyl), their pharmaceutically acceptable salts and/or isomers, tautomers, solvates or isotopic variations thereof. The compounds are useful for the treatment of cancers.Type: ApplicationFiled: September 21, 2020Publication date: February 11, 2021Inventors: Stephane Rocchi, Rachid Benhida, Robert Ballotti, Magali Plaisant, Cyril Ronco, Antoine Millet
-
Patent number: 10815207Abstract: The present invention relates to compound of general formula (I) R1 is selected from H, aryl and alkyl, R2 is selected from H, alkyl, aryl and CO—R6; R3 is selected from H, halogen, alkyl, alkenyl, alkynyl, aryl, NHR7, NR7R8, OR7 and SR7; R4 is selected from (C6-C12) alkyl, (C2-C12) alkenyl, (C2-C12) alkynyl and (C6-C10) aryl, R5 represents H, R6, aryl, OH, OR6, O-aryl, SH, SR6, S-aryl, CN, NO2, CF3, COOR6, SO2NR6R7, CONR6R7, NH2, NHR6, NH-aryl, NR6R7, NHCOR6 or aminoacyl; R6 is alkyl optionally substituted with halogen, OH, SH, NH2, O-alkyl, S-alkyl, NH-alkyl or NH-di(alkyl); R7 and R8 identical or different are H or alkyl optionally substituted with halogen, OH, SH, NH2, O-alkyl, S-alkyl, NH-alkyl or NH-di (alkyl), their pharmaceutically acceptable salts and/or isomers, tautomers, solvates or isotopic variations thereof. The compounds are useful for the treatment of cancers.Type: GrantFiled: July 22, 2016Date of Patent: October 27, 2020Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite Nice Sophia Antipolis, Centre National de la Recherche Scientifique (CNRS)Inventors: Stephane Rocchi, Rachid Benhida, Robert Ballotti, Magali Plaisant, Cyril Ronco, Antoine Millet
-
Publication number: 20180215723Abstract: The present invention relates to compound of general formula (I) R1 is selected from H, aryl and alkyl, R2 is selected from H, alkyl, aryl and CO—R6; R3 is selected from H, halogen, alkyl, alkenyl, alkynyl, aryl, NHR7, NR7R8, OR7 and SR7; R4 is selected from (C6-C12) alkyl, (C2-C12) alkenyl, (C2-C12) alkynyl and (C6-C10) aryl, R5 represents H, R6, aryl, OH, OR6, O-aryl, SH, SR6, S-aryl, CN, NO2, CF3, COOR6, SO2NR6R7, CONR6R7, NH2, NHR6, NH-aryl, NR6R7, NHCOR6 or aminoacyl; R6 is alkyl optionally substituted with halogen, OH, SH, NH2, O-alkyl, S-alkyl, NH-alkyl or NH-di(alkyl); R7 and R8 identical or different are H or alkyl optionally substituted with halogen, OH, SH, NH2, O-alkyl, S-alkyl, NH-alkyl or NH-di (alkyl), their pharmaceutically acceptable salts and/or isomers, tautomers, solvates or isotopic variations thereof. The compounds are useful for the treatment of cancers.Type: ApplicationFiled: July 22, 2016Publication date: August 2, 2018Inventors: Stephane Rocchi, Rachid Benhida, Robert Ballotti, Magali Plaisant, Cyril Ronco, Antoine Millet
-
Patent number: 9567310Abstract: The present invention relates to compound of general formula (1) wherein R1 represents C6-C10 aryl comprising one or two fused rings, wherein from 2 to 5 carbon atoms may be replaced with a heteroatom selected from O, S and NR6, and eventually substituted with from 5 to 11 substituents selected from R6, halo, CN, NO2, CF3, OCF3, COOR6, OCOR6, SO2NR6R7, CONR6R7, NR6R7, NR6COR7, (CH2)p—NR6R7, (CH2)p—OR6 and (CH2)pSR6, as well as, if appropriate, their pharmaceutically acceptable salts and/or isomers, tautomers, solvates or isotopic variations thereof. The compounds are useful for the treatment of cancers.Type: GrantFiled: November 8, 2013Date of Patent: February 14, 2017Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHARCHE MEDICALE), UNIVERSITE NICE SOPHIA ANTIPOLIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Stephane Rocchi, Robert Ballotti, Rachid Benhida, Michael Cerezo, Maria Duca, Jean-Patrick Joly
-
Publication number: 20160030367Abstract: The invention relates to an AMPK activator (such as for instance metformin) for use in preventing metastasis in a patient suffering from a cancer, wherein said patient has a non-mutated p53 gene or lacks a mutant form of the p53 protein. The invention also relates to an AMPK activator for use in improving the survival time of a patient suffering from a cancer, wherein said patient has a non-mutated p53 gene or lacks a mutant form of the p53 protein.Type: ApplicationFiled: March 14, 2014Publication date: February 4, 2016Inventors: Stephane Rocchi, Robert Ballotti, Michael Cerezo
-
Patent number: 9194003Abstract: The present invention relates to a mutant of MITF which is useful as a marker for predisposition to the development of cancer and to uses thereof in diagnosis and preventive treatments, sumoylation being reduced or absent in this mutant.Type: GrantFiled: December 21, 2010Date of Patent: November 24, 2015Assignees: INSTITUT GUSTAVE ROUSSY, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE SOPHIA NICE ANTIPOLISInventors: Robert Ballotti, Corine Bertolotto, Brigitte Bressac De Paillerets, Mahaut De Lichy, Fabienne Lesueur
-
Publication number: 20150284347Abstract: The present invention relates to compound of general formula (1) wherein R1 represents C6-C10 aryl comprising one or two fused rings, wherein from 2 to 5 carbon atoms may be replaced with a heteroatom selected from O, S and NR6, and eventually substituted with from 5 to 11 substituents selected from R6, halo, CN, NO2, CF3, OCF3, COOR6, OCOR6, SO2NR6R7, CONR6R7, NR6R7, NR6COR7, (CH2)p—NR6R7, (CH2)p—OR6 and (CH2)pSR6, as well as, if appropriate, their pharmaceutically acceptable salts and/or isomers, tautomers, solvates or isotopic variations thereof. The compounds are useful for the treatment of cancers.Type: ApplicationFiled: November 8, 2013Publication date: October 8, 2015Inventors: Stephane Rocchi, Robert Ballotti, Rachid Benhida, Michael Cerezo, Maria Duca, Jean-Patrick Joly
-
Publication number: 20140199292Abstract: The present invention relates to products and compositions containing (i) a chemotherapeutic agent and (ii) at least an active compound chosen from CCL2 inhibitors, CCR2 inhibitors, NF-?B inhibitors, PARP-1 inhibitors and ATM inhibitors, as a combined preparation for simultaneous, separate or sequential use for inhibiting tumor development caused by tumor cell senescence induced by said chemotherapeutic agent. The invention also refers to a method for monitoring the response to a chemotherapeutic agent of a patient suffering from a cancer, and to a method for predicting the tumor size evolution and/or the onset of metastasis in a patient suffering from a cancer.Type: ApplicationFiled: March 14, 2012Publication date: July 17, 2014Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)Inventors: Corine Bertolotto-Ballotti, Robert Ballotti, Mickael Ohanna, Sandy Giuliano
-
Publication number: 20130059916Abstract: The invention relates to a compound of formula (I), wherein the radicals R1 to R2 have the meaning according to claim 1, and/or physiologically acceptable salts thereof for the use for the prevention and/or treatment of cancer.Type: ApplicationFiled: May 6, 2010Publication date: March 7, 2013Inventors: Stephane Rocchi, Vincent Aroles, Robert Ballotti, Tijana Tomic
-
Publication number: 20120252904Abstract: The present invention relates to a mutant of MITF which is useful as a marker for predisposition to the development of cancer and to uses thereof in diagnosis and preventive treatments, sumoylation being reduced or absent in this mutant.Type: ApplicationFiled: December 21, 2010Publication date: October 4, 2012Applicants: INSTITUT GUSTAVE ROUSSY, UNIVERSITE SOPHIA NICE ANTIPOLIS, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE )Inventors: Robert Ballotti, Corine Bertolotto, Brigitte Bressac De Paillerets, Mahaut De Lichy, Fabienne Lesueur